Associated Papers
Missense VKOR mutants exhibit severe warfarin resistance but lack VKCFD via shifting to an aberrantly reduced state.
Li S et al.
Blood Advances, 2023
Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact.
Chiasson MA et al.
Elife, 2020
Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.
Shen G et al.
Journal of Thrombosis and Haemostasis : Jth, 2018
Structural Modeling Insights into Human VKORC1 Phenotypes.
Czogalla KJ et al.
Nutrients, 2015
Identification of VKORC1 genotype leading to resistance to tecarfarin.
Matagrin B et al.
Journal of Clinical Pharmacology, 2014
Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces.
Czogalla KJ et al.
Blood, 2013
Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay.
Bevans CG et al.
Biochimica Et Biophysica Acta, 2013
VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity.
Hodroge A et al.
Journal of Thrombosis and Haemostasis : Jth, 2012
Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.
Watzka M et al.
Journal of Thrombosis and Haemostasis : Jth, 2011
Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reductase-like1.
Van Horn WD
Critical Reviews in Biochemistry and Molecular Biology, 0
Select a paper to view details